Relamorelin
Overview
Relamorelin is a synthetic pentapeptide ghrelin receptor agonist designed to stimulate growth hormone secretion and promote gastric motility. It binds selectively to the growth hormone secretagogue receptor type 1a (GHS-R1a), mimicking the action of endogenous ghrelin. The peptide was developed primarily for the treatment of diabetic gastroparesis and other disorders of gastric emptying, with potential applications in cachexia and functional dyspepsia.
Key Research Findings
Phase 2 trials in diabetic gastroparesis demonstrated improvements in gastric emptying and symptom reduction, with data presented at Digestive Disease Week in 2017. Despite initial promise, development was discontinued by the sponsor in 2020. Clinical evidence supports prokinetic activity, though no regulatory approval has been obtained.
Subcutaneous injection
Investigational
Interested in Relamorelin?
Find a verified provider experienced with Relamorelin protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Relamorelin ProviderRelated Peptides
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life from minutes to approximately 6-8 days. CJC-1295 stimulates pulsatile GH release from the anterior pituitary by binding to GHRH receptors while preserving the natural GH secretory pattern and negative feedback mechanisms.
Ipamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH release. Unlike other GH secretagogues, ipamorelin does not significantly affect ACTH, cortisol, or prolactin levels, making it one of the most specific GH-releasing peptides. It works synergistically with GHRH analogs like CJC-1295.
Sermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid hormone. Sermorelin stimulates the pituitary to produce and release growth hormone through the natural GHRH receptor pathway, preserving the hypothalamic-pituitary feedback axis. It maintains physiological pulsatile GH secretion patterns.
Tesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability. Tesamorelin specifically targets visceral adipose tissue reduction by stimulating lipolysis through GH-mediated pathways. It is the only FDA-approved treatment for HIV-associated lipodystrophy.